ea0090p759 | Thyroid | ECE2023
Koukoula Chrysoula
, Papalou Olga
, Diamantopoulos Aristidis
, Beka Aikaterini
, Baikousi Dimitra
, Antonopoulou Vasiliki
, Ntali Georgia
, Stratigou Theodora
, Rontogianni Phoebe
, Datseris Ioannis
, Vassiliadi Dimitra
, Tsagarakis Stylianos
Radioiodine treatment is the cornerstone of differentiated thyroid cancer (DTC) management. A number of thyroid cancers, however, become radioiodine-refractory (RAIR) and these represent about 60% of advanced DTCs and are responsible for the vast majority of DTC mortality. RAIR DTC has limited therapeutic options, mainly tyrosine kinase inhibitors that are associated with moderate efficacy and considerable toxicity. Reinducing NIS expression (redifferentiation) with the aim of...